Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O6UY
|
|||
| Drug Name |
Pemigatinib
|
|||
| Synonyms |
Unii-Y6BX7BL23K; UNII-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828
Click to Show/Hide
|
|||
| Indication | Cholangiocarcinoma [ICD-11: 2C12.10; ICD-10: C22.1] | Approved | [1] | |
| Bladder cancer [ICD-11: 2C94; ICD-9: 188] | Phase 2 | [2] | ||
| Myeloproliferative syndrome [ICD-11: 2A22; ICD-10: D47.1] | Phase 2 | [2] | ||
| Company |
Incyte Wilmington, DE
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H27F2N5O4
|
|||
| Canonical SMILES |
CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5
|
|||
| InChI |
1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)
|
|||
| InChIKey |
HCDMJFOHIXMBOV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1513857-77-6
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.